Colorectal cancer is the second largest cause of cancer mortality in the United States [1] , and the third largest cause in Japan [2] . At the time of diagnosis, 13% of patients will present with synchronous liver metastasis [3] and another 7.2% of patients with Stage I-III disease will develop metachronous liver metastasis even after a primary curative operation [4] .
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Improved surgical expertise and advances in chemotherapy combination regimens, such as FOLFOX and FOLFIRI, have contributed to profound improvement in outcomes in liver metastasis of colorectal cancer [5, 6] . In order to obtain much better survival rates, several strategies combining surgery and new molecular targeted drugs, such as bevacizumab and cetuximab, have been investigated.
On the other hand, recent technological developments have provided much information regarding tumor biology, with tools to scrutinize cell-matrix interactions, cell-cell interactions, signal pathways, angiogenesis, cytokines, etc. [7] . In addition, an important role of immature myeloid cells in an early stage of metastasis has been reported [8] . Based on these findings of tumor biology, new molecular or cellular targeted drugs will be developed.
Here we present two current topics in colorectal liver metastasis: molecular mechanism of liver metastasis and treatment strategy for liver metastasis. The former focuses on several key roles of cytokines in liver metastasis, and the latter on aggressive resection combined with chemotherapy. We hope these review articles will lead to an understanding of current topics and facilitate research in this field.
